Evidence map›Paper›PMID 37330006›Full record

ReviewThe American journal of the medical sciences2023

Untangling the web of glioblastoma treatment resistance using a multi-omic and multidisciplinary approach.

Donald M Miller, Kavitha Yadanapudi, Veeresh Rai, Shesh N Rai, Joseph Chen, Hermann B Frieboes, Adrianna Masters, Abigail McCallum, Brian J Williams

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The American journal of the medical sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Donald M MillerBrown Cancer Center, University of Louisville, Louisville, KY, USA; Department of Medicine, School of Medicine, University of Louisville, Louisville, KY, USA. Electronic address: donaldmi@ulh.org.
Kavitha YadanapudiBrown Cancer Center, University of Louisville, Louisville, KY, USA; Department of Medicine, School of Medicine, University of Louisville, Louisville, KY, USA.
Veeresh RaiBrown Cancer Center, University of Louisville, Louisville, KY, USA.
Shesh N RaiBrown Cancer Center, University of Louisville, Louisville, KY, USA; Biostatistics and Informatics Shared Resources, University of Cincinnati Cancer Center, Cincinnati, OH, USA; Cancer Data Science Center of University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Joseph ChenBrown Cancer Center, University of Louisville, Louisville, KY, USA; Department of Bioengineering, Speed School of Engineering, University of Louisville, Louisville, KY, USA.
Hermann B FrieboesBrown Cancer Center, University of Louisville, Louisville, KY, USA; Department of Bioengineering, Speed School of Engineering, University of Louisville, Louisville, KY, USA; Center for Preventative Medicine, University of Louisville, Louisville, KY, USA.
Adrianna MastersBrown Cancer Center, University of Louisville, Louisville, KY, USA; Department of Radiation Oncology, University of Louisville, Louisville, KY, USA.
Abigail McCallumBrown Cancer Center, University of Louisville, Louisville, KY, USA; Department of Neurosurgery, University of Louisville, Louisville, KY, USA.
Brian J WilliamsBrown Cancer Center, University of Louisville, Louisville, KY, USA; Department of Neurosurgery, University of Louisville, Louisville, KY, USA.

Funding

The role of ECM-mediated mechanosignaling on regional immunosuppression in GBMP20GM135004 · NIGMS · UNIVERSITY OF LOUISVILLE · PI Sharmila Nair · 2020 to 2026
$21.1M
Identifying and targeting a novel mechanism of chemotherapy-induced immunotherapeutic resistance in non-small cell lung cancerR01CA272772 · NCI · UNIVERSITY OF LOUISVILLE · PI Kavitha Yaddanapudi · 2023 to 2026
$1.4M
Overcoming resistance to cancer immunotherapy by targeting MDSC-derived adenosineR21CA245560 · NCI · UNIVERSITY OF LOUISVILLE · PI YADDANAPUDI, KAVITHA · 2020 to 2021
$368k
NCI NIH HHS R01 CA272772NCI NIH HHS R21 CA245560NIGMS NIH HHS P20 GM135004
6 · The paper itself

Abstract

Glioblastoma (GBM), the most common human brain tumor, has been notoriously resistant to treatment. As a result, the dismal overall survival of GBM patients has not changed over the past three decades. GBM has been stubbornly resistant to checkpoint inhibitor immunotherapies, which have been remarkably effective in the treatment of other tumors. It is clear that GBM resistance to therapy is multifactorial. Although therapeutic transport into brain tumors is inhibited by the blood brain barrier, there is evolving evidence that overcoming this barrier is not the predominant factor. GBMs generally have a low mutation burden, exist in an immunosuppressed environment and they are inherently resistant to immune stimulation, all of which contribute to treatment resistance. In this review, we evaluate the contribution of multi-omic approaches (genomic and metabolomic) along with analyzing immune cell populations and tumor biophysical characteristics to better understand and overcome GBM multifactorial resistance to treatment.

Indexed as

Brain NeoplasmsGlioblastomaHumansImmunotherapyMultiomicsGlioblastomaImmune cellsMetabolomicsMulti-omic analysisProteomicsTumor microenvironment

Identifiers

PMID37330006
PMCPMC13097186

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.